tbuckley/cabot-search huggingface dataset:
Abstract 19050: Inhibition of CaMKII blocks Inducible Ventricular Tachycardia/Fibrillation and Triggered Activity in a Canine Model of Myocardial Ischemia
Authors: James B Martins, Ashok K Chaudhary, Michael A Kwofie, Elizabeth D Luczak, Mark E Anderson
Journal: Circulation (2014)

Introduction:  Ventricular tachycardia or fibrillation (VT/VF) of focal origin due to triggered activity (TA) from delayed afterdepolarizations is reproducibly inducible after anterior coronary artery occlusion in the dog. Calcium/Calmodulin Dependent Protein Kinase II (CaMKII) has been implicated in arrhythmias in small animal models. Here, we investigated the effect of inhibition of CaMKII on inducible VT/VF in our model.   Methods:  25 chloralose anesthetized dogs received either an inhibitor of CaMKII, KN-93 at 2 mcg/kg IV, or saline for time controls. Endocardium from ischemic sites (3-D mapping utilizing customized Matlab 7.11 software) was sampled for oxidized CaMKII or studied in vitro with standard microelectrode techniques. Results (mean ± SE, *=p   Conclusion:  In ischemic VT/VF, KN-93 specifically blocked all inducible focal VT/VF due to TA without evidence of conduction or refractory period change in our large animal model of ischemia.
Abstract 419: The role of histone methyltransferase G9a in chemotherapeutic drugs-induced DNA damage
Authors: Chia-Wen Liu
Journal: Cancer Research (2014)

Abstract Head and neck squamous cell carcinoma (HNSCC) is one of the serious life-threatening diseases in the world. In addition to surgery, the conventional treatments for oral cancer includes radiation and chemotherapy, which usually act by induction of DNA damage. However, approximately one-third of treated patients will experience local or regional recurrence. G9a is a histone methyltransferase responsible for mono- or di-methylation of lysine 9 in histone H3. Our recent work has demonstrated that G9a level is highly correlated with aggressiveness and poor prognosis of lung, ovarian and colon cancer patients in Taiwanese population. Here, we found that G9a expression in HNSCC is upregulated and positively correlated with poor prognosis. Moreover, knockdown of G9a resulted in decrease cell survival and cologenic capacity following treating with chemotherapeutic drug, hydroxyurea and etoposide. Futhermore, depletion of G9a caused sustained phosphorylation of γ-H2AX after etoposide treatment. Together, We suggest that G9a may contribute to HNSCC proliferation by improvement of DNA double break repair. Our study paves the way for exploring the blockade of G9a overexpression as a novel approach for the prevention and treatment of HNSCC. Citation Format: Chia-Wen Liu. The role of histone methyltransferase G9a in chemotherapeutic drugs-induced DNA damage. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 419. doi:10.1158/1538-7445.AM2014-419
New Positive Inotropic Agents in the Treatment of Congestive Heart Failure
Authors: Wilson S. Colucci, Richard F. Wright, Eugene Braunwald
Journal: New England Journal of Medicine (1986)

Newer Phosphodiesterase InhibitorsAmong the most promising recent developments in positive inotropic agents has been the description of a class of drugs that have both potent positive inotropic and vasodilatory effects (Table 1). Initial reports have documented that these drugs do not inhibit sodium–potassium ATPase, nor are their inotropic effects diminished by reserpine-induced depletion of endogenous catecholamine stores, pretreatment with beta-adrenergic or alpha-adrenergic blockers, H2 antagonists, agents that block prostaglandin synthesis, or drugs that selectively block the fast inward sodium channels. Hence, they are often referred to as "non-glycoside, non-sympathomimetic" positive inotropic agents. Although structurally dissimilar from one another . . .
Prospects for feeding the world Commentary: Bread for the world---another view
Authors: T. Dyson, M. King
Journal: BMJ (1999)

# Prospects for feeding the world {#article-title-2} In 1950 the world's population numbered 2.5 billion. In 1999 it is around 6 billion. It will be roughly 8 billion by 2025. And it could reach between 9 and 10 billion by the middle of the coming century. Arguably this is the most important development of our time, with immense implications for the global environment and the prospects for feeding the world. #### Summary points Population growth is the most important factor fuelling the global demand for more food to be produced The population of sub-Saharan Africa probably faces the grimmest prospects for receiving adequate nutrition The world trade in cereals must increase substantially to meet projected increases in demand The pace of increase in cereal yields is continuing with no signs of a slowdown The outlook for feeding the world would be improved if the growth in population decreased This paper addresses the prospects for feeding the world to the year 2025. It builds on the results of a two year research fellowship funded by the UK Economic and Social Research Council.1 The data used throughout were those provided by the United Nations Food and Agriculture Organisation and the UN Population Fund. As well as analysing statistical data, the research involved talking to technical specialists and farmers throughout the world In the early 1990s the UN Food and Agriculture Organisation estimated that there were roughly 800 million undernourished people in the world.2 Most of these people live in the developing world, mainly in the Indian subcontinent and sub-Saharan Africa. However, the organisation's estimate may be too high. The number was obtained through a tortuous statistical exercise which was loaded with assumptions. Also, an organisation concerned with food production may have a tendency to err on the side of overestimation. Certainly, in the past the organisation changed its criteria for … Correspondence to: M King, 1 bis Rue du Tir, Geneva 1204, Switzerland
Professor Sir George Alberti
Authors: Katherine Burke
Journal: BMJ (2004)

Health tsars: spin or substance?: Eight health directors (“tsars”) were appointed from 1999 to 2002. Katherine Burke asked them to summarise their achievements and other people to assess their work. A ninth “tsar”, Dr Sue Roberts, was appointed in March 2003 to cover diabetes. The full text is accessible at www.bmj.com

   ![][1] 

Professor Sir George Alberti 

National clinical director for emergency access 

Appointed: September 2002 

My …

 [1]: /embed/graphic-1.gif
PU.1 and the Granulocyte- and Macrophage Colony-Stimulating Factor Receptors Play Distinct Roles in Late-Stage Myeloid Cell Differentiation
Authors: Karen L. Anderson, Kent A. Smith, Hugh Perkin, Gary Hermanson, Carol-Gay Anderson, Douglas J. Jolly, Richard A. Maki, Bruce E. Torbett
Journal: Blood (1999)
Medical Toxicology: Diagnosis and Treatment of Human Poisoning.
Authors: Matthew J. Ellenhorn, Donald G. Barceloux
Journal: Annals of Internal Medicine (1988)

General Approach to the Poisoned Patient Introduction and Initial Evaluation. Diagnostic Services. Gut Decontamination. Enhancement and Elimination. Antidotes. Supportive Care. Pharmacokinetics. Toxic Exposure During Pregnancy. Therapeutic Drugs Acetaminophen. Anti-Arrhythmic Agents. Anti-Coagulants. Anti-Convulsants. Anti-Hypertensive Drugs. Anti-Infective Drugs. Anti-Depressants. Disulfiram. H 2 -Receptor Antagonists. Hypoglycemics and Insulin. Muscle Relaxants. Neuroleptic Drugs. Non-Steroidal Anti-Inflammatory Drugs. (NSAID's). Over-the-counter Products. Salicylates. Sedative-Hypnotics. Theophylline. Thyroid Hormones. Drugs of Abuse Amphetamines. Cocaine. Lysergic Acid Diethylamide (LSD). Marijuana. Opiates. Opioids and Designer Drugs. Phencyclidine (PCP). Chemical Products Alcohols and Glycols. Airborne Toxins. Household Products. Hydrocarbon Products. Metals and Related Compounds. Pesticides. Natural Toxins Envenomations from Bites and Stings. Reptiles. Anthropods. Insects. Fish. Foodborne Toxins. Plants - Mycotoxins - Mushrooms.
Abstract 3538: Obligate haploinsufficiency of the microRNA-processing molecule dicer1 in a murine colitis-associated tumorigenesis model
Authors: Takeshi Yoshikawa, Motoyuki Otsuka, Kazuhiko Koike
Journal: Cancer Research (2014)

Abstract Background: A widespread downregulated expression of microRNAs (miRNAs) is commonly observed in human cancers. Similarly, deregulated expression of miRNA-processing pathway components, which results in the reduction of global miRNA expression, may also be associated with tumorigenesis. Thus, we hypothesized that the deregulation of microRNA-processing molecule Dicer1 in intestinal epithelial cells may accelerate intestinal inflammation-associated tumorigenesis. Methods &amp; Results: We constructed Dicer1 gene-disrupted mice with monoallelic and biallelic loss of its locus. Inflammation-associated colon tumors were induced by azoxymethane (AOM) injection with the treatment by three cycles of Dextran Sulfate Sodium (DSS). 1) Dicer1 protein expression and subsequent mature miRNA levels in the isolated intestinal epithelial cells were inversely correlated with the number of intact Dicer1 alleles. 2) Although the severity of inflammation after the induction in this model was comparable in control and Dicer1-mutant mice, the number of colon tumors was significantly higher in heterozygous mice but not in homozygous mice. 3) Because the expression levels of Dicer1 were retained in tumors and its surrounding tissues even after induction of colitis-associated tumors, the effects of Dicer1 deletion on tumorigenesis were considered as cell-autonomous. 4) While the expression levels of representative oncogenes and tumor suppressor genes were in most cases inversely correlated with the expression levels of Dicer1, some genes were not affected by Dicer1 deletion. Conclusion: Specific ablation of Dicer1 in intestinal epithelial cells accelerates intestinal inflammation-associated tumorigenesis. However, this effect was apparent only when a single copy of Dicer1 was deleted, but not with complete Dicer1 gene ablation. Generally, complete loss of the function of most tumor suppressor genes is advantageous for tumor development. However, our results suggest that, in case of Dicer1 gene, complete loss is deleterious for cancer development, while its partial inactivation promotes tumor formation. This unique “obligate haploinsufficient role” colitis-associated colon tumor of Dicer and miRNAs needs further attention to elucidate the pathogenesis of tumorigenesis related with deregulated miRNAs. Citation Format: Takeshi Yoshikawa, Motoyuki Otsuka, Kazuhiko Koike. Obligate haploinsufficiency of the microRNA-processing molecule dicer1 in a murine colitis-associated tumorigenesis model. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 3538. doi:10.1158/1538-7445.AM2014-3538
Abstract 19094: Antihypertensive Properties of Subcutaneous M-ANP, a Novel Designer Atrial Natriuretic Peptide, in a Canine Model of Chronic Angiotensin-II Induced Hypertension
Authors: Giuseppe Puccia, Jeson S Sangaralingham, Gail J Harty, Alessandro Cataliotti, Tomoko Ichiki, Lorenzo Malatino, John C Burnett
Journal: Circulation (2014)

Introduction: Blood pressure (BP) control remains low despite combination therapy in resistant hypertension (RH). Thus, there is an unmet need for novel strategies targeting RH. Recently we have reported that M-ANP, a novel Mayo engineered ANP-based peptide, possesses greater and more sustained biological actions compared to ANP and is more resistant to neprilysin degradation. The current study was designed to investigate for the first time the efficacy of a single daily subcutaneous (SQ) injection of M-ANP using a chronic canine model of hypertension induced by angiotensin II (Ang-II). Hypothesis: We hypothesize that a daily SQ M-ANP injection would have potent BP lowering and renal enhancing properties in our chronic hypertensive canine model. Methods: We induced hypertension in canines (n=5) by continuous Ang II (80 ng/kg/min) osmotic mini-pump administration for 24 days. Continuous 24 hour mean BP (MBP) was measured by telemetry and a 24 hour urine collection was used to assess urinary volume, sodium (Na) and cGMP, the second messenger for the ANP system. M-ANP was administered SQ for 5 days (10μg/kg/day). Data are mean±SE. ΨP&lt;0.05 Ang II Day 16 vs. baseline; *P&lt;0.05 Ang II Day 16 vs. M-ANP (Table 1). Results: Chronic Ang II administration resulted in model of severe hypertension, with an increase in MBP from 112±2 to 157±2 mmHg (day 16). As seen in Table 1, M-ANP significantly reduced MBP, significantly increased plasma cGMP as well as urinary cGMP excretion, urinary volume rate (UV) and urinary Na excretion (UNa), without significant changes in heart rate (HR). Furthermore, there was a trend for plasma ANP to increase and plasma aldosterone to decrease with SQ M-ANP injection. Conclusions: This study demonstrates for the first time that chronic SQ administration of M-ANP reduces BP, activates plasma cGMP, and increases UV and UNa, without significant changes in HR in an experimental model of chronic hypertension.
The Reduction of Domestic Flies.
Authors: Edward Halford Ross
Journal: JAMA (1913)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
EOSINOPHILIC GRANULOMA OF RIB
Authors: D R WEIR
Journal: Annals of Internal Medicine (1951)

Case Reports1 July 1951EOSINOPHILIC GRANULOMA OF RIBDAVID R. WEIR, M.D.DAVID R. WEIR, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-35-1-233 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptPrevious to 1940, eosinophilic granuloma of bone had not been recognized as a definite clinical entity. Since then over 50 cases have been reported, and a number of reviews of the subject have appeared in the recent literature.1, 2, 3Clinically and radiographically, eosinophilic granuloma may simulate a wide variety of bone diseases, ranging from simple cyst4to apparent malignant bone destruction such as existed in the case reported here. Although follow-up studies on most of the reported cases are necessarily incomplete, it is probable that the lesion usually is essentially benign and may be eradicated by surgical excision, curettage...Bibliography1. DundonWilliamsLaipply CCHATC: Eosinophilic granuloma of bone, Radiology 47: 433, 1946. CrossrefMedlineGoogle Scholar2. BakerHoughtonWissingBetts WJJDERH: Eosinophilic granuloma. Report of a case with x-ray evidence of rapid progression, New England J. Med. 238: 626, 1948. CrossrefMedlineGoogle Scholar3. MaurerDe Stefano EGA: Eosinophilic granuloma of rib, J. Thoracic Surg. 17: 350, 1948. CrossrefGoogle Scholar4. GrantHouseCrandell ARRKWB: Eosinophilic granuloma of rib, New England J. Med. 240: 541, 1949. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: *Received for publication June 14, 1949.From the Department of Medicine, University Hospitals of Cleveland, Ohio. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byEosinophilic Granuloma of BoneEosinophilic granuloma of the rib 1 July 1951Volume 35, Issue 1Page: 233-236KeywordsBoneGranulomasHospital medicineLesionsRibs ePublished: 1 December 2008 Issue Published: 1 July 1951 PDF downloadLoading ...
Membrane-derived microvesicles from embryonic stem cells as a new tool to improve ex vivo expansion and maintenance of hematopoietic stem cells
Authors: Janina Ratajczak, Magdalena Kucia, Mariusz Z. Ratajczak
Journal: Cancer Research (2004)

Proc Amer Assoc Cancer Res, Volume 45, 2004

2792 

Membrane-derived vesicles (MV) are released from the surface of activated eukaryocytic cells and, as we demonstrated recently, MV derived from platelets are physiological components of the hematopoietic environment, exerting pleiotropic effects on surrounding cells ( Blood 2001, 98, 3143; Exp. Hematol 2002, 30, 450) . Since the development of embryoid bodies is regulated by close cell-to-cell interactions among embryonic stem cells (ES) (by membrane-expressed molecules), we hypothesized that MV derived from ES (ES-MV) could express stem cell-specific molecules that affect self-renewal and expansion of hematopoietic stem cells (HSC). We found that ES-MV (10 μg/ml) isolated from murine ES cells (ES-D3) in serum-free cultures significantly i) enhanced survival and improved expansion of murine Sca-1+ early HSC and, when cultured for 7 days, survived significantly better and formed more CFU-Mix, CFU-GM, BFU-E and CFU-GM colonies than control cells (p<0.0001). Further, at the molecular level, ES-MV strongly stimulated in murine Sca-1+ and human CD34+ cells phosphorylation of MAPK p42/44 and serine-threonine kinase AKT and upregulated expression of mRNA for early embryonic/hematopoietic transcription factors such as Oct-4, HoxB4 and GATA-2. Moreover, Western-blot analysis revealed that ES-MV express the Wnt protein suggesting that Wnt signaling plays an essential role in cell expansion. Encouraged by these observations we employed ES-MV as a new tool to expand umbilical cord blood (UCB)-derived HSC responsible for long-term engraftment in vivo . In these experiments UCB CD34+ cells were cultured in a serum-free medium, QBSF-60, containing ES-MV (10 μg/ml) or a combination of optimal doses of SCF, FLT-3, TPO, IL-3, IL-6, IL-11, G-CSF and EPO. We found that ES-MV were as effective in expanding CD34+ CD38- DR- cells as the optimal combination which was of SCF + FLT-3 + TPO + IL-6. Since ES-MV allowed efficient expansion of HSC we postulate that they could find clinical application for expansion of HSC from UCB. Studies to identify which biologically active protein/lipid components of ES-MV and which stem cell-expressed and perhaps unique regulatory molecules/ligands are expressed by ES-MV in addition to Wnt are in progress.
925. Electroporation Mediated Gene Transfer of Human Interleukin-10 to Skeletal Muscle Reduces Acute Rejection in Rat Cardiac Allografts
Authors: Reza Tavakoli, Amiq Gazdhar, Jaroslaw Pierog, Anna Bagdannova, Mathias Gugger, Steven Hyde, Michele Genoni, Ralph Schmid
Journal: Molecular Therapy (2004)

Background Electroporation-mediated transfer of plasmid DNA has been demonstrated to enhance gene transduction dramatically. The aim of this study was to investigate the impact of overexpression of human IL-10 (hIL-10) on acute rejection of cardiac allografts in the rat.
A memorable patient: "When can I go home?"
Authors: A. Abdala
Journal: BMJ (2002)

It was a routine referral to the rheumatology clinic: a general practitioner had requested advice about the management of arthritic pain in a 78 year old woman. We met her at the Friday afternoon clinic, when she came with her daughter in law. Her joint pain had improved since she had seen her general practitioner. She had osteoarthritic changes in her hands and knees, as expected, but no features of inflammatory arthritis. She was remarkably thin and had recently lost a lot of weight. I wondered whether she had an underlying malignancy. She agreed …
Effectiveness and pharmacokinetics of low-dose all-trans retinoic acid (25 mg/m2) in acute promyelocytic leukemia
Authors: S Castaigne, P Lefebvre, C Chomienne, E Suc, F Rigal-Huguet, C Gardin, A Delmer, E Archimbaud, H Tilly, M Janvier
Journal: Blood (1993)
Ambient air pollution, lung function, and airway responsiveness in asthmatic children
Authors: Despo Ierodiakonou, Antonella Zanobetti, Brent A. Coull, Steve Melly, Dirkje S. Postma, H. Marike Boezen, Judith M. Vonk, Paul V. Williams, Gail G. Shapiro, Edward F. McKone, Teal S. Hallstrand, Jane Q. Koenig, Jonathan S. Schildcrout, Thomas Lumley, Anne N. Fuhlbrigge, Petros Koutrakis, Joel Schwartz, Scott T. Weiss, Diane R. Gold
Journal: Journal of Allergy and Clinical Immunology (2015)
Differences in the robustness of clusters involving the Mycobacterium tuberculosis strains most frequently isolated from immigrant cases in Madrid
Authors: N. Alonso Rodríguez, M. Martínez Lirola, F. Chaves, J. lñigo, M. Herranz, V. Ritacco, E. Bouza, D. García de Viedma
Journal: Clinical Microbiology and Infection (2010)
Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression
Authors: Martina Sanlorenzo, Igor Vujic, Adil Daud, Alain Algazi, Matthew Gubens, Sara Alcántara Luna, Kevin Lin, Pietro Quaglino, Klemens Rappersberger, Susana Ortiz-Urda
Journal: JAMA Dermatology (2015)

Immunomodulatory anticancer drugs, such as the anti-programmed death-1 drug pembrolizumab, have shown promising results in trials, and more patients will receive such treatments. Little is known about cutaneous adverse events (AEs) caused by these drugs and their possible correlation with treatment response.To describe the frequency and spectrum of cutaneous AEs linked with pembrolizumab and their possible correlation with treatment response.A single-institution, retrospective medical record review was conducted of patients with cancer who were treated with pembrolizumab from March 1, 2011, to May 28, 2014. The review comprised 83 consecutive patients who were enrolled in 2 clinical trials, received at least 1 dose of pembrolizumab, and had at least 1 follow-up visit. Patients were grouped according to the following therapeutic regimen for pembrolizumab: 43 received 10 mg/kg every 3 weeks, 24 received 10 mg/kg every 2 weeks, and 16 received 2 mg/kg every 3 weeks. Sixty-six patients were treated for melanoma, 15 patients for lung cancer, 1 patient for prostate cancer, and 1 patient for Merkel cell carcinoma. Median follow-up was 15 weeks (range, 2-105 weeks). The analysis was conducted from March 1 to September 30, 2014.Occurrence, severity, and type of cutaneous AEs, as well as disease progression and response to pembrolizumab treatment.Thirty-five patients (42%) developed cutaneous AEs attributed to pembrolizumab. The most common cutaneous AEs were macular papular eruption (24 [29%]), pruritus (10 [12%]), and hypopigmentation (7 [8%]). All 7 patients who developed hypopigmentation were treated for melanoma. Survival analyses showed that patients who developed cutaneous AEs had significantly longer progression-free intervals in all 3 groups (pembrolizumab, 10 mg/kg, every 3 weeks, P = .001; pembrolizumab, 10 mg/kg, every 2 weeks, P = .003; pembrolizumab, 2 mg/kg, every 3 weeks, P = .009) compared with patients who did not develop cutaneous AEs.Pembrolizumab therapy was associated with cutaneous AEs in 42% of patients. The development of cutaneous AEs, especially of hypopigmentation in patients with melanoma, could point toward better treatment response.